Bianca Sänger
A5039815672- SARS-CoV-2 and COVID-19 Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Animal Virus Infections Studies
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Toxin Mechanisms and Immunotoxins
- Viral gastroenteritis research and epidemiology
- Immune Cell Function and Interaction
- Influenza Virus Research Studies
- CRISPR and Genetic Engineering
- RNA and protein synthesis mechanisms
- SARS-CoV-2 detection and testing
BioNTech (Germany)
2020-2023
BioNTech (United States)
2021
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number mutations, with 10 amino acid changes spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing either...
Abstract Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis by activating cytotoxic T-cell–mediated antitumor immunity. DuoBody-PD-L1×4-1BB (GEN1046) is investigational, first-in-class bispecific immunotherapy agent designed...
Abstract To contain the coronavirus disease 2019 (COVID-19) pandemic, a safe and effective vaccine against new severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is urgently needed in quantities sufficient to immunise large populations. In this study, we report design, preclinical development, immunogenicity anti-viral protective effect rhesus macaques of BNT162b2 candidate. contains an LNP-formulated nucleoside-modified mRNA that encodes spike glycoprotein captured its prefusion...
Abstract Recently, a new SARS-CoV-2 lineage called B.1.1.7 has emerged in the United Kingdom that was reported to spread more efficiently than other strains. This variant an unusually large number of mutations with 10 amino acid changes spike protein, raising concerns its recognition by neutralizing antibodies may be affected. Here, we investigated SARS-CoV-2-S pseudoviruses bearing either Wuhan reference strain or protein sera 16 participants previously trial mRNA-based COVID-19 vaccine...
The ongoing COVID-19 pandemic is leading to the discovery of hundreds novel SARS-CoV-2 variants daily. While most do not impact course pandemic, some pose an increased risk when acquired mutations allow better evasion antibody neutralisation or transmissibility. Early detection such high-risk (HRVs) paramount for proper management pandemic. However, experimental assays determine immune and transmissibility characteristics new are resource-intensive time-consuming, potentially delays in...
Despite the preclinical promise of CD40 and 4-1BB as immuno-oncology targets, clinical efforts evaluating agonists monotherapy have found limited success. DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting conditional stimulation to enhance priming reactivation tumor-specific immunity in patients with cancer.
Abstract A safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b candidates, which contain lipid-nanoparticle (LNP) formulated nucleoside-modified mRNA encoding SARS-CoV-2 spike glycoprotein-derived immunogens. BNT162b1 encodes a soluble, secreted, trimerised receptor-binding domain (RBD-foldon). BNT162b2 full-length transmembrane glycoprotein, locked its prefusion...
Abstract The ongoing COVID-19 pandemic is leading to the discovery of hundreds novel SARS-CoV-2 variants on a daily basis. While most do not impact course pandemic, some pose significantly increased risk when acquired mutations allow better evasion antibody neutralisation in previously infected or vaccinated subjects transmissibility. Early detection such high (HRVs) paramount for proper management pandemic. However, experimental assays determine immune and transmissibility characteristics...
<div>Abstract<p>Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis by activating cytotoxic T-cell–mediated antitumor immunity. DuoBody-PD-L1×4-1BB (GEN1046) is investigational, first-in-class bispecific...
<div>Abstract<p>Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis by activating cytotoxic T-cell–mediated antitumor immunity. DuoBody-PD-L1×4-1BB (GEN1046) is investigational, first-in-class bispecific...
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors